An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Psychiatrically stable subjects with schizophrenia who have had a suboptimal response to current treatment
Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.
Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.
You may not be if
History of seizures or of a condition with risk of seizures.
Subjects with schizophrenia that have not responded at all to current treatment.
Pregnant or nursing females, and females of child bearing potential.
Clareo Health | An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
